Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19256882 | 0.88 | CTSS (0.43) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL21376008 | 0.86 | CTSS (0.44) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL1993119 | 0.83 | CTSS (0.46) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL266022 | 0.83 | CTSK (0.51) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL266021 | 0.83 | CTSK (0.51) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL118384 | 0.83 | CTSK (0.51) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL10376395 | 0.82 | CTSS (0.45) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL10321617 | 0.82 | CTSS (0.45) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL7269720 | 0.81 | SYK (0.46) | CTSSCTSKSYKMEN1GAA | |
| SCHEMBL2798709 | 0.81 | PPARG (0.44) | CTSSCTSKSYKMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| US-20210253547-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2021-08-19 | — | — | US | disclosed |
| US-20210253547-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-11021456-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126626-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126626-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010011853-A2 | BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011853-A2 | BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2010-01-28 | — | — | US | disclosed |
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | CTSS 1460/4885CTSK 1094/4885SYK 4355/4885 |
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | CTSS 2435/4885CTSK 1527/4885SYK 2107/4885 |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | CTSS 1460/4885CTSK 1094/4885SYK 4355/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | CTSS 1460/4885CTSK 1094/4885SYK 4355/4885 |
| US-20210253547-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | CTSS 2435/4885CTSK 1527/4885SYK 2107/4885 |
| US-11021456-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | PRKCQ, UACA, BCAT2 | CTSS 2435/4885CTSK 1527/4885SYK 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.